Laryngeal Preservation with Boron Neutron Capture Therapy for Metachronous Second Primary Head and Neck Cancer in the Pharyngolaryngeal Region Within a Previously Irradiated Field

Background/Objectives: The occurrence of metachronous second primary head and neck cancer within a previously irradiated field presents a challenging clinical problem because reirradiation can cause severe toxicities. Boron neutron capture therapy (BNCT) may offer a curative treatment option for such tumors while minimizing the risk of severe toxicity. This study aimed to evaluate the feasibility of laryngeal preservation using BNCT for these tumors. Methods: Patients with metachronous second primary cancer in the pharyngeal or laryngeal region within a previously irradiated field who received BNCT between June 2020 and January 2022 were retrospectively included. Overall survival, laryngeal preservation, and local control were estimated using the Kaplan–Meier method. Results: All 11 patients achieved a complete response. The follow-up duration for surviving patients exceeded 4 years. The 4-year overall survival, laryngeal preservation, and local control rates were 81.8%, 80.0%, and 70.0%, respectively. No late toxicities of grade 3 or higher were observed. Among the three patients with local recurrence, two underwent salvage surgery (in one case, the patient underwent surgery after receiving BNCT once more). Local control was achieved in both patients without serious toxicities. Conclusions: BNCT for patients with metachronous second primary head and neck cancer achieved a high response rate and a high rate of laryngeal function preservation, with toxicity remaining within acceptable limits. Moreover, salvage surgery was feasible after BNCT. These findings suggest that BNCT may serve as a larynx-sparing treatment option for metachronous second primary head and neck cancer arising within a previously irradiated field.

Authors

Institutions

Publication Details

Journal
Cancers
Published
2026-11-20
DOI
https://doi.org/10.3390/cancers18223717
Primary Topic
Boron Compounds in Chemistry
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Laryngeal Preservation with Boron Neutron Capture Therapy for Metachronous Second Primary Head and Neck Cancer in the Pharyngolaryngeal Region Within a Previously Irradiated Field

Ryohei Kato, Yoshiaki Takagawa, Takahiro Katō, Yuki Narita et al.
4 links
Cancers
Boron Compounds in Chemistry
article

Laryngeal Preservation with Boron Neutron Capture Therapy for Metachronous Second Primary Head and Neck Cancer in the Pharyngolaryngeal Region Within a Previously Irradiated Field

Ryohei Kato, Yoshiaki Takagawa, Takahiro Katō, Yuki Narita, Ichiro Seto, Kanako Takayama, Tomoaki Motoyanagi, Shinya Komori, Akihiko Takeuchi, Yoshihiro Takai, Yuhei Yamazaki, Shunsuke Komatsu, Takashi Ono
article en

Abstract

Background/Objectives: The occurrence of metachronous second primary head and neck cancer within a previously irradiated field presents a challenging clinical problem because reirradiation can cause severe toxicities. Boron neutron capture therapy (BNCT) may offer a curative treatment option for such tumors while minimizing the risk of severe toxicity. This study aimed to evaluate the feasibility of laryngeal preservation using BNCT for these tumors. Methods: Patients with metachronous second primary cancer in the pharyngeal or laryngeal region within a previously irradiated field who received BNCT between June 2020 and January 2022 were retrospectively included. Overall survival, laryngeal preservation, and local control were estimated using the Kaplan–Meier method. Results: All 11 patients achieved a complete response. The follow-up duration for surviving patients exceeded 4 years. The 4-year overall survival, laryngeal preservation, and local control rates were 81.8%, 80.0%, and 70.0%, respectively. No late toxicities of grade 3 or higher were observed. Among the three patients with local recurrence, two underwent salvage surgery (in one case, the patient underwent surgery after receiving BNCT once more). Local control was achieved in both patients without serious toxicities. Conclusions: BNCT for patients with metachronous second primary head and neck cancer achieved a high response rate and a high rate of laryngeal function preservation, with toxicity remaining within acceptable limits. Moreover, salvage surgery was feasible after BNCT. These findings suggest that BNCT may serve as a larynx-sparing treatment option for metachronous second primary head and neck cancer arising within a previously irradiated field.

CancersVol. 18(22)
Fukushima Medical University (JP)
Good health and well-being
Boron Compounds in Chemistry
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon